Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface.

Lysine-plasminogen (Lys-PLG), the plasmin-modified form of native glutamic acid-plasminogen (Glu-PLG), displays enhanced binding affinity for fibrin and also enhanced activation by urokinase and tissue plasminogen activator. We previously demonstrated high-affinity, specific, and functional binding of Glu-PLG as well as tissue plasminogen activator to cultured human umbilical vein endothelial cells (HUVEC). In the present study, we demonstrate binding of Lys-PLG to HUVEC, as well as conversion of Glu-PLG to Lys-PLG at the cell surface. Binding of Lys-PLG to HUVEC was saturable, reversible, epsilon-aminocaproic acid-sensitive, and involved two saturable sites with Kd's of 142 pM and 120 nM, respectively. Upon incubation with Glu-PLG, HUVEC, as well as endothelium in situ, partially converted the ligand to a Lys-PLG-like species. Conversion by HUVEC was blocked by diisopropyl-fluorophosphate, but not by other serine protease inhibitors, including alpha 2-plasmin inhibitor. Eluates of intact umbilical cord vessels contained Lys-PLG by immunoblot analysis. Lys-PLG was also identified immunohistochemically on the endothelial surface of vessels from a variety of normal and inflamed tissues. Thus, endothelial cells appear to actively modify circulating Glu-PLG, bind Lys-PLG to their surface, and thus enhance the fibrinolytic potential of the blood vessel wall.

[1]  E. Plow,et al.  Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis , 1988 .

[2]  F. Blasi.  Surface Receptors for Urokinase Plasminogen Activator , 1988 .

[3]  K. Hajjar,et al.  Binding of tissue plasminogen activator to cultured human endothelial cells. , 1987, The Journal of clinical investigation.

[4]  E. Plow,et al.  Receptor Mediated Binding of the Fibrinolytic Components, Plasminogen and Urokinase, to Peripheral Blood Cells , 1987, Thrombosis and Haemostasis.

[5]  C. Broder,et al.  Identification of a specific receptor for plasmin on a group A streptococcus , 1987, Infection and immunity.

[6]  R. Mellgren,et al.  Calcium‐dependent proteases: an enzyme system active at cellular membranes? , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  G. Dini,et al.  Interaction of urokinase with specific receptors abolishes the time of commitment to terminal differentiation of murine erythroleukaemia (Friend) cells , 1987, British journal of haematology.

[8]  D. Belin,et al.  Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface , 1987, The Journal of cell biology.

[9]  P. Burtin,et al.  The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study , 1987, International journal of cancer.

[10]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[11]  E. Jaffe,et al.  Binding of plasminogen to cultured human endothelial cells. , 1986, The Journal of biological chemistry.

[12]  E. Appella,et al.  Autocrine saturation of pro-urokinase receptors on human A431 cells , 1986, Cell.

[13]  J. White,et al.  Plasminogen interacts with human platelets through two distinct mechanisms. , 1986, The Journal of clinical investigation.

[14]  G. Dini,et al.  The Mr 17500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells. , 1986, Biochimica et biophysica acta.

[15]  T. Nakamura,et al.  A unique trypsin-like protease associated with plasma membranes of rat liver. , 1986, The Journal of biological chemistry.

[16]  D. Collen,et al.  A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. , 1985, The Journal of biological chemistry.

[17]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Plow,et al.  Binding and activation of plasminogen on the platelet surface. , 1985, The Journal of biological chemistry.

[19]  P. Burtin,et al.  The plasmin system in human colonic tumors: An immunofluorescence study , 1985, International journal of cancer.

[20]  G. Dini,et al.  Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. , 1985, Cancer research.

[21]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[22]  G. Osikowicz,et al.  Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54,000) from cultured human endothelial cells indistinguishable from urinary urokinase. , 1984, The Journal of biological chemistry.

[23]  H. Chapman,et al.  Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. , 1984, The Journal of clinical investigation.

[24]  I. Horváth,et al.  Interaction of plasmin with endothelial cells. , 1984, The Biochemical journal.

[25]  F. Castellino.  Biochemistry of Human Plasminogen , 1984, Seminars in thrombosis and hemostasis.

[26]  E. Shaw,et al.  Isolation and characterization of a trypsin-like serine proteinase from the membranes of Walker 256 carcino-sarcoma cells. , 1983, The Biochemical journal.

[27]  P. McKee,et al.  The binding of human plasminogen to fibrin and fibrinogen. , 1983, The Journal of biological chemistry.

[28]  M. Brown,et al.  Visualization of lipoprotein receptors by ligand blotting. , 1983, The Journal of biological chemistry.

[29]  D. Rifkin,et al.  Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Brown,et al.  Immunoblot analysis of low density lipoprotein receptors in fibroblasts from subjects with familial hypercholesterolemia. , 1982, The Journal of biological chemistry.

[31]  D. Loskutoff,et al.  Cultured bovine endothelial cells produce both urokinase and tissue- type plasminogen activators , 1982, The Journal of cell biology.

[32]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[33]  H. Chapman,et al.  Macrophage fibrinolytic activity: Identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor , 1982, Cell.

[34]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[35]  R. Priore,et al.  The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. , 1979, The Journal of biological chemistry.

[36]  B. Wiman,et al.  Molecular mechanism of physiological fibrinolysis , 1978, Nature.

[37]  G. Markus,et al.  Comparison of some properties of native (Glu) and modified (Lys) human plasminogen. , 1978, The Journal of biological chemistry.

[38]  D. Loskutoff,et al.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Fenton,et al.  Equilibrium binding of thrombin to platelets. , 1976, Biochemistry.

[40]  B. Wiman,et al.  Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-aminohexanoic acid. , 1973, European journal of biochemistry.

[41]  B. Wiman,et al.  Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. , 1973, European journal of biochemistry.

[42]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[43]  B. M. Turner.  Use of alkaline phosphatase-conjugated antibodies for detection of protein antigens on nitrocellulose filters. , 1986, Methods in enzymology.

[44]  D. Collen,et al.  Interaction of Plasminogen Activators and Inhibitors with Plasminogen and Fibrin , 1982, Seminars in thrombosis and hemostasis.

[45]  T. Osawa,et al.  Degradation of band-3 glycoprotein in vitro by a protease isolated from human erythrocyte membrane. , 1982, European journal of biochemistry.

[46]  C. Brown,et al.  Effects of acrosin inhibitors on the soluble and membrane-bound forms of ram acrosin, and a reappraisal of the role of the enzyme in fertilization. , 1976, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[47]  B. Zweifach,et al.  Micropressures and capillary filtration coefficients in single vessels of the cremaster muscle of the rat. , 1970, Microvascular research.